60 Degrees Pharmaceuticals Inc (SXTP)

$1.26 -0.04 (-3.08%)
Market Cap 5.17M
Revenue (ttm) 680,000.00
Net Income (ttm) -7.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,169.12%
Debt to Equity Ratio 0.00
Volume 35,800
Avg Vol 680,780
Day's Range N/A - N/A
Shares Out 4.10M
Stochastic %K 13%
Beta 2.71
Analysts Sell
Price Target $7.00

Company Profile

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidi...

Industry: Biotechnology
Sector: Healthcare
Phone: 202 327 5422
Address:
1025 Connecticut Avenue NW, Suite 1000, Washington, United States
Valuestocktrades
Valuestocktrades Aug. 22 at 6:58 PM
$INTC Forbes says $SXTP https://www.forbes.com/sites/greatspeculations/2025/08/20/intel-stock-to-60/ Get excited
0 · Reply
JAG_2_Trade
JAG_2_Trade Aug. 22 at 1:22 PM
$SXTP 60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 19 at 1:08 PM
$SXTP 60 Degrees Pharma Signs Clinical Trial Agreement With Icahn School Of Medicine At Mount Sinai In New York City As Central Site For Phase II Clinical Study Of Tafenoquine In Treating Chronic Babesiosis
0 · Reply
MrTicker
MrTicker Aug. 19 at 12:56 PM
$SXTP 60 Degrees Pharma Signs Clinical Trial Agreement With Icahn School Of Medicine At Mount Sinai In New York City As Central Site For Phase II Clinical Study Of Tafenoquine In Treating Chronic Babesiosis BENZINGA 7:56 AM ET 8/19/2025
0 · Reply
MrTicker
MrTicker Aug. 19 at 12:54 PM
$SXTP 60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis GLOBENEWSWIRE 7:54 AM ET 8/19/2025
0 · Reply
MrTicker
MrTicker Aug. 15 at 8:11 PM
$SXTP Form PRE 14A 60 DEGREES PHARMACEUTICA For: Aug 15 10K WIZARD 3:05 PM ET 8/15/2025 http://archive.fast-edgar.com/20250815/AT2JI22CLZ22N95Z28Z22ZY2SG8HZ222Z276 Filed on: August 15, 2025
0 · Reply
MrTicker
MrTicker Aug. 13 at 8:16 PM
$SXTP 60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results GLOBENEWSWIRE 3:14 PM ET 8/13/2025 A now resolved supply disruption led to Q2 net product revenue decline but higher profitability due to increased usage of a cash-pay distribution model $1.97 million cash on hand, runway through March 31, 2026 WASHINGTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.(SXTP) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today its financial results for the second quarter of 2025, ended June 30, 2025.
0 · Reply
indybucfan
indybucfan Aug. 13 at 8:04 PM
$SXTP hanging on!
0 · Reply
d_risk
d_risk Aug. 13 at 7:46 PM
$SXTP - 60 DEGREES PHARMACEUTICALS, INC. - 10Q - Updated Risk Factors SXTP flags new risks of potential dilution and stock price pressure from July 2025 warrants, specifying types and share amounts tied to the latest offering. #Pharmaceuticals #EquityPressure #MarketRisk #Warrants #StockDilution 🟢 Added 🟠 Removed https://d-risk.ai/SXTP/10-Q/2025-08-13
0 · Reply
DayTrade_4Life
DayTrade_4Life Aug. 12 at 12:31 AM
Stocks with Recent Surge in Short Interest. $MRNY, $SONN, $NDRA, $SXTP, $SGN
1 · Reply
Latest News on SXTP
60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 21, 2025, 8:31 AM EDT - 3 days ago

60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

Aug 19, 2025, 8:54 AM EDT - 5 days ago

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

Aug 13, 2025, 4:14 PM EDT - 10 days ago

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

Jul 16, 2025, 4:01 PM EDT - 5 weeks ago

60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

Jul 15, 2025, 9:10 AM EDT - 5 weeks ago

60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

Jul 15, 2025, 7:01 AM EDT - 5 weeks ago

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

Jun 4, 2025, 8:56 AM EDT - 2 months ago

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

Jun 3, 2025, 8:49 AM EDT - 2 months ago

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

May 15, 2025, 4:31 PM EDT - 3 months ago

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

Apr 22, 2025, 8:44 AM EDT - 4 months ago

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

Apr 10, 2025, 8:31 AM EDT - 4 months ago

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

Apr 8, 2025, 8:31 AM EDT - 4 months ago

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Feb 21, 2025, 9:00 AM EST - 6 months ago

60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

FTHM

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

Feb 20, 2025, 10:36 AM EST - 6 months ago

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

Feb 11, 2025, 12:59 PM EST - 6 months ago

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 6, 2025, 2:07 PM EST - 7 months ago

60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 5, 2025, 9:22 AM EST - 7 months ago

60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 30, 2025, 2:20 PM EST - 7 months ago

60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

Jan 28, 2025, 8:01 AM EST - 7 months ago

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

Jan 8, 2025, 8:02 AM EST - 8 months ago

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

Dec 23, 2024, 8:57 AM EST - 8 months ago

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital

Dec 11, 2024, 8:56 AM EST - 9 months ago

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital

VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Dec 2, 2024, 4:05 PM EST - 9 months ago

VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

VSEE

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nov 22, 2024, 9:00 AM EST - 9 months ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

CANF

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results

Nov 14, 2024, 2:31 PM EST - 10 months ago

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

Oct 3, 2024, 9:02 AM EDT - 11 months ago

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

Hyliion Holdings And 2 Other Stocks Under $5 Executives Are Buying

Sep 12, 2024, 7:19 AM EDT - 1 year ago

Hyliion Holdings And 2 Other Stocks Under $5 Executives Are Buying

HYLN COCH

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Sep 4, 2024, 8:00 AM EDT - 1 year ago

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

Aug 28, 2024, 2:48 PM EDT - 1 year ago

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results

Aug 14, 2024, 11:01 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

Aug 12, 2024, 9:12 AM EDT - 1 year ago

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split

Aug 6, 2024, 9:26 AM EDT - 1 year ago

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split

60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support

Jul 25, 2024, 9:02 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

Jul 19, 2024, 8:29 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

Jul 9, 2024, 6:31 AM EDT - 1 year ago

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind

Jun 27, 2024, 7:59 AM EDT - 1 year ago

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind

Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind

May 30, 2024, 7:59 AM EDT - 1 year ago

Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind

60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study

May 20, 2024, 7:59 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study

60 Degrees Pharmaceuticals Announces First Quarter 2024 Results

May 15, 2024, 1:45 PM EDT - 1 year ago

60 Degrees Pharmaceuticals Announces First Quarter 2024 Results

60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases

May 8, 2024, 7:59 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required

May 2, 2024, 7:59 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required

60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis

Apr 3, 2024, 7:58 AM EDT - 1 year ago

60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis

60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024

Mar 14, 2024, 7:59 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024

60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris

Feb 20, 2024, 7:59 AM EST - 1 year ago

60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris

60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer

Feb 8, 2024, 7:59 AM EST - 1 year ago

60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer

WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

Jan 31, 2024, 12:00 PM EST - 1 year ago

WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering

Jan 31, 2024, 11:15 AM EST - 1 year ago

60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering

WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

Jan 30, 2024, 9:45 AM EST - 1 year ago

WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering

Jan 30, 2024, 9:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering

60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting

Jan 22, 2024, 7:59 AM EST - 1 year ago

60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting

Valuestocktrades
Valuestocktrades Aug. 22 at 6:58 PM
$INTC Forbes says $SXTP https://www.forbes.com/sites/greatspeculations/2025/08/20/intel-stock-to-60/ Get excited
0 · Reply
JAG_2_Trade
JAG_2_Trade Aug. 22 at 1:22 PM
$SXTP 60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 19 at 1:08 PM
$SXTP 60 Degrees Pharma Signs Clinical Trial Agreement With Icahn School Of Medicine At Mount Sinai In New York City As Central Site For Phase II Clinical Study Of Tafenoquine In Treating Chronic Babesiosis
0 · Reply
MrTicker
MrTicker Aug. 19 at 12:56 PM
$SXTP 60 Degrees Pharma Signs Clinical Trial Agreement With Icahn School Of Medicine At Mount Sinai In New York City As Central Site For Phase II Clinical Study Of Tafenoquine In Treating Chronic Babesiosis BENZINGA 7:56 AM ET 8/19/2025
0 · Reply
MrTicker
MrTicker Aug. 19 at 12:54 PM
$SXTP 60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis GLOBENEWSWIRE 7:54 AM ET 8/19/2025
0 · Reply
MrTicker
MrTicker Aug. 15 at 8:11 PM
$SXTP Form PRE 14A 60 DEGREES PHARMACEUTICA For: Aug 15 10K WIZARD 3:05 PM ET 8/15/2025 http://archive.fast-edgar.com/20250815/AT2JI22CLZ22N95Z28Z22ZY2SG8HZ222Z276 Filed on: August 15, 2025
0 · Reply
MrTicker
MrTicker Aug. 13 at 8:16 PM
$SXTP 60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results GLOBENEWSWIRE 3:14 PM ET 8/13/2025 A now resolved supply disruption led to Q2 net product revenue decline but higher profitability due to increased usage of a cash-pay distribution model $1.97 million cash on hand, runway through March 31, 2026 WASHINGTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.(SXTP) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today its financial results for the second quarter of 2025, ended June 30, 2025.
0 · Reply
indybucfan
indybucfan Aug. 13 at 8:04 PM
$SXTP hanging on!
0 · Reply
d_risk
d_risk Aug. 13 at 7:46 PM
$SXTP - 60 DEGREES PHARMACEUTICALS, INC. - 10Q - Updated Risk Factors SXTP flags new risks of potential dilution and stock price pressure from July 2025 warrants, specifying types and share amounts tied to the latest offering. #Pharmaceuticals #EquityPressure #MarketRisk #Warrants #StockDilution 🟢 Added 🟠 Removed https://d-risk.ai/SXTP/10-Q/2025-08-13
0 · Reply
DayTrade_4Life
DayTrade_4Life Aug. 12 at 12:31 AM
Stocks with Recent Surge in Short Interest. $MRNY, $SONN, $NDRA, $SXTP, $SGN
1 · Reply
PaulLaurent
PaulLaurent Aug. 11 at 7:29 PM
📈⚠️ Stocks with Recent Surge in Short Interest ⚠️📈 $MRNY $LRHC $SONN $SXTP $NDRA
1 · Reply
Zboquid
Zboquid Aug. 8 at 1:54 PM
$SXTP https://www.sacbee.com/press-releases/article311632906.html
0 · Reply
GoSportsJimbo
GoSportsJimbo Aug. 6 at 2:11 PM
$SXTP I can see this one bouncing 400-600% any random day.
1 · Reply
Love_To_Learn
Love_To_Learn Aug. 5 at 11:22 AM
$SXTP why u being silly
0 · Reply
StockTock24
StockTock24 Aug. 4 at 10:40 PM
$SXTP Pure speculation but with the commercials and recent press of Hollywood with Lyme. I can see this memeing
0 · Reply
CandleOps
CandleOps Aug. 4 at 3:07 PM
$SXTP your time to rise
1 · Reply
PaulLaurent
PaulLaurent Jul. 30 at 7:03 PM
📈⚠️ Stocks with Recent Surge in Short Interest ⚠️📈 $LRHC $SXTP $NDRA $FIEE $SQFT
1 · Reply
Antley4
Antley4 Jul. 30 at 5:36 PM
$SXTP as a long time chronic lyme sufferer, i hope the find a solution and the stock rockets
0 · Reply
jniravel
jniravel Jul. 30 at 2:05 AM
$SXTP SXTP appears to have highest short-term upside potential if there's positive pipeline news, FDA feedback, or clinical trial updates—especially given low float and current price well below warrant pricing.
0 · Reply
jniravel
jniravel Jul. 29 at 2:51 PM
$SXTP Time to get in here
0 · Reply
myuri
myuri Jul. 29 at 2:00 AM
$SXTP This was dumped even with the $1.90 offering and warrants!
0 · Reply
jniravel
jniravel Jul. 29 at 1:37 AM
$SXTP still waiting here
0 · Reply